Genome Editing Techniques and Their Therapeutic Applications

Clinical Pharmacology and Therapeutics

Volumn 101, Issue 1, 2017, Pages 42-51

  Calos, M P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RECOMBINASE;

ARTICLE; DNA STRUCTURE; DOUBLE STRANDED DNA BREAK; GENE THERAPY; GENETIC PROCEDURES; GENOME EDITING; HUMAN; NONHUMAN; PRIORITY JOURNAL; RETROVIRIDAE; TRANSPOSON; BIOLOGICAL THERAPY; CHEMISTRY; GENE DELETION; GENE EDITING; GENETIC DISEASES, INBORN; GENETICS; GENOMICS; HUMAN GENOME; NEOPLASMS; NUCLEOTIDE SEQUENCE; PROCEDURES;

BASE SEQUENCE; CELL- AND TISSUE-BASED THERAPY; DNA; DNA BREAKS, DOUBLE-STRANDED; GENE DELETION; GENE EDITING; GENETIC DISEASES, INBORN; GENETIC THERAPY; GENOME, HUMAN; GENOMICS; HUMANS; NEOPLASMS;

EID: 85002693088     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.542     Document Type: Article

References (67)

1. Belfort, M. & Bonocora, R.P. Homing endonucleases: from genetic anomalies to programmable genomic clippers. Methods Mol. Biol. 1123, 1–26 (2014).
2. Szostak, J.W., Orr-Weaver, T.L., Rothstein, R.J. & Stahl, F.W. The double-strand-break repair model for recombination. Cell 33, 25–35 (1983).
3. Roberts, R.J. How restriction enzymes became the workhorses of molecular biology. Proc. Natl. Acad. Sci. U. S. A. 102, 5905–5908 (2005).
4. Jacquier, A. & Dujon, B. An intron-encoded protein is active in a gene conversion process that spreads an intron into a mitochondrial gene. Cell 41, 383–394 (1985).
5. Colleaux, L., D'Auriol, L., Galibert, F. & Dujon, B. Recognition and cleavage site of the intron-encoded omega transposase. Proc. Natl. Acad. Sci. U. S. A. 85, 6022–2026 (1988).
6. Hinnen, A., Hicks, J.B. & Fink, G.R. Transformation of yeast. Proc. Natl. Acad. Sci. U. S. A. 75, 1929–1933 (1978).
7. Smithies, O., Gregg, R.G., Boggs, S.S. Koralewski, M.A. & Kucherlapati, R. Insertion of DNA sequences into the human chromosomal β-globin locus by homologous recombination. Nature 317, 230–234 (1985).
8. Capecchi, M.R. Altering the genome by homologous recombination. Science 244, 1288–1292 (1989).
9. Rouet, P., Smih, F. & Jasin, M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 91, 6064–6068 (1994).
10. Choulika, A., Perrin, A., Dujon, B. & Nicolas, J.F. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of Saccharomyces cerevisiae. Mol. Cell Biol. 15, 1968–1973 (1995).
11. Takeuchi, R. et al. Tapping natural reserves of homing endonucleases for targeted gene modification. Proc. Natl. Acad. Sci. U. S. A. 108, 13077–13082 (2011).
12. Takeuchi, R., Choi, M. & Stoddard, B. Redesign of extensive protein-DNA interfaces of meganucleases using iterative cycles of in vitro compartmentalization. Proc. Natl. Acad. Sci. U. S. A. 111, 4061–4066 (2014).
13. Carroll, D. Genome engineering with targetable nucleases. Annu. Rev. Biochem. 83, 409–439 (2014).
14. Pabo, C.O., Peisach, E. & Grant, R.A. Design and selection of novel Cys2His2 zinc finger proteins. Annu. Rev. Biochem. 70, 313–340 (2001).
15. Kim, Y-G., Cha, J. & Chandrasegaran, S. Hybrid restriction enzymes: zinc finger fusions to FokI cleavage domain. Proc. Natl. Acad. Sci. U. S. A. 93, 1156–1160 (1996).
16. Bibikova, M., Beumer, K., Trautman, J.K. & Carroll, D. Enhancing gene targeting with designed zinc finger nucleases. Science 300, 764 (2003).
17. Urnov, F.D., Rebar, E.J., Holmes, M.C., Zhang, H.S. & Gregory, P.D. Genome editing with engineered zinc finger nucleases. Nat. Rev. Genet. 11, 636–646 (2010).
18. Moscou, M.J. & Bogdanove, A.J. A simple cipher governs DNA recognition by TAL effectors. Science 326, 1501 (2009).
19. Boch, J., Schholze, H., Schornack, S., Landgraf, A., Hahn, S., Kay, S. et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 326, 1509–1512 (2009).
20. Bogdanove, A.J. & Voytas, D.F. TAL effectors: Customizable proteins for DNA targeting. Science 333, 1843–1846 (2011).
21. Joung, J.K. & Sander, J.D. TALENs: A widely applicable technology for targeted genome editing. Nat. Rev. Mol. Cell Biol. 14, 49–55 (2013).
22. Boissel, S. et al. megaTALs: a rare-cleaving nuclease architecture for therapeutic genome engineering. Nucl. Acids Res. 42, 2591–2601 (2014).
23. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J.A., Charpentier, E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).
24. Cong, L. et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823. (2013).
25. Mali, P. et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).
26. Doudna, J.A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).
27. Gao, F., Shen, X.Z., Jiang, F., Wu, Y. & Han, C. DNA-guided genome editing using the Natronobacterium gregoryi Argonaute. Nat. Biotechnol. 34, 768–773 (2016).
28. Martinez-Galvez, G., Ata, H., Campbell, J.M. & Ekker, S.C. ssDNA and the Argonautes: the quest for the next golden editor. Hum. Gene Ther. 27, 419–422 (2016).
29. Geisinger, J.M., Turan, S., Hernandez, S., Spector, L.P. & Calos, M.P. In vivo blunt-end cloning through CRISPR/Cas9-facilitated non-homologous end-joining. Nucl. Acids Res. 44, e76 (2016).
30. Turan, S., Farruggio, A.P., Srifa, W., Day, J.W. & Calos, M.P. Precise correction of disease mutations in induced pluripotent stem cells derived from patients with limb girdle muscular dystrophy. Mol. Ther. 24, 685–696 (2016).
31. Chen, X. & Goncalves, M.A.F.V. Engineered viruses as genome editing devices. Mol. Ther. 24, 447–457 (2016).
32. Tebas, P. et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N. Engl. J. Med. 370, 901–910 (2014).
33. Elbadawy, H.M. et al. Gene transfer of integration defective anti-HAS-1 meganuclease to human corneas ex vivo. Gene Ther. 21, 272–281 (2014).
34. Fesnak, A., June, C.H. & Levine, B.L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat. Rev. Cancer 16, 566–581 (2016).
35. Poirot, L. et al. (2015). Multiplex genome-edited T cell manufacturing platform for “off-the-shelf” adoptive T-cell immunotherapies. Cancer Res. 75, 3853–3864.
36. Long, C. et al. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 351, 400–403 (2016).
37. Nelson, C.E. et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 351, 403–407 (2016).
38. Tabebordbar, M. et al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 351, 307–311 (2016).
39. Xu, L. et al. CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice. Mol. Ther. 24, 564–569 (2016).
40. Calos, M.P. The CRISPR way to think about Duchenne's. N. Engl. J. Med. 374, 1684–1686 (2016).
41. Cicalese, M.P. & Aiuti, A. Clinical applications of gene therapy for primary immunodeficiencies. Hum. Gene Ther. 26, 210–219 (2015).
42. Hacein-Bey-Abina, S. et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene theapy of SCID-X1. J. Clin. Invest. 118, 3132–3142.
43. Yu, K.R., Natanson, H. & Dunbar, C.E. Gene editing of human hematopoietic stem and progenitor cells: promise and potential hurdles. Hum. Gene Ther. (2016); e-pub ahead of print. doi: 10.1089/hum/2016.107.
44. Naldini, L., Trono, D. & Verma, I.M. Lentiviral vectors, two decades later. Science 353, 1101–1102 (2016).
45. Cavazzana-Calvo, M. et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature 467, 318–322 (2010).
46. Mansilla-Soto, J., Riviere, I., Boulad, F. & Sadelain, M. Cell and gene therapy for the Beta-thalassemias: advances and prospects. Hum. Gene Ther. 27, 295–304 (2016).
47. Ammar, I. Izsvak, Z. & Ivics, Z. The Sleeping Beauty transposon toolbox. Methods Mol. Biol. 859, 229–240 (2012).
48. Singh, H., Moyes, J.S., Huis, M.H. & Cooper, L.J. Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor. Cancer Gene Ther. 22, 95–100 (2015).
49. Kebriaei, P. et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J. Clin. Invest. 126, 3363–3376 (2016).
50. Loperfido, M. et al. piggyBac transposons expressing full-length human dystrophin enable genetic correction of dystrophic mesoangioblasts. Nucl. Acids Res. 44, 744–760 (2016).
51. Sauer, B. & Henderson, N. Cre-stimulated recombination at loxP-containing DNA sequences placed into the mammalian genome. Nucl. Acids Res. 17, 147–161 (1989).
52. Groth, A.C., Olivares, E.C., Thyagarajan, B. & Calos, M.P. A phage integrase directs efficient site-specific integration in human cells. Proc. Natl. Acad. Sci U. S. A. 97, 5995–6000 (2000).
53. Grindley, N.D.F, Whiteson, K.L. & Rice, P.A. Mechanisms of site-specific recombination. Annu. Rev. Biochem. 75, 567–605 (2006).
54. Karpinski, J. et al. Directed evolution of a recombinase that excises the provirus of most HIV-1 primary isolates with high specificity. Nat. Biotechnol. 34, 401–409 (2016).
55. Thyagarajan, B., Olivares, E.C., Hollis, R.P., Ginsburg, D.S. & Calos, M.P. Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol. Cell. Biol. 21, 3926–3934 (2001).
56. Chalberg, T.W. et al. Integration specificity of phage phiC31 integrase in the human genome. J. Mol. Biol. 357, 28–48 (2006).
57. Chavez, C.L. & Calos, M.P. Therapeutic applications of the phiC31 integrase system. Curr. Gene Ther. 11, 375–381 (2011).
58. Calos, M.P. Phage integrases for genome editing. In Genome Editing: The Next Step in Gene Therapy (eds. Cathomen, T., Hirsch, M., Porteus, M., ASGCT and Springer). Adv. Exp. Med. Biol. 895, 81–91 (2016).
59. Bertoni, C. et al. Enhancement of plasmid-mediated gene therapy for Duchenne muscular dystrophy by directed plasmid integration. Proc. Natl. Acad. Sci. U. S. A. 103, 419–424 (2006).
60. Zhao, C. et al. Recombinase-mediated reprogramming and dystrophin gene addition in mdx mouse induced pluripotent stem cells. PLoS One 9, e96279 (2014).
61. Zhu, F. et al. DICE, an efficient system for iterative genomic editing in human pluripotent stem cells. Nucl. Acids Res. 42, e34 (2014).
62. Komor, A.C., Kim, Y.B., Packer, M.S., Zuris, J.A. & Liu, D.R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
63. Sirk, S.J., Gaj, T., Jonsson, A. Mercer, A.C. & Barbas, C.F. Expanding the zinc-finger recombinase reperatoire: Directed evolution and mutational analysis of serine recombinase specificity. Nucl. Acids Res. 42, 4755–4766 (2014).
64. Chalkind, B., Bessen, J.L., Thompson, D.B., Hu, J.H. & Liu, D. A programmable Cas9-serine recombinase fusion protein that operates on DNA sequences in mammalian cells. Nucl. Acids Res. (2016); e- pub ahead of print. doi:10.1093/nar//gkw707.
65. Sclimenti, C.R., Thyagarajan, B. & Calos, M.P. Directed evolution of a recombinase for improved genomic integration at a native human sequence. Nucl. Acids Res. 29, 5044–5051 (2001).
66. Keravala, A. et al. Mutants of phiC31 integrase with enhanced efficiency and specificity. Mol. Ther. 17, 112–120 (2009).
67. Farruggio, A.P. & Calos, M.P. Serine integrase chimeras with activity in E. coli and HeLa cells. Biol. Open 3, 895–903 (2014).